Citadel Advisors
TVRD

Citadel Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Citadel Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14
Closed -$129 – 15483
2024
Q2 		$129 Buy
+14
New +$334 ﹤0.01% 14091
2024
Q1 		– Sell
-319
Closed -$8.54K – 15604
2023
Q4 		$8.54K Sell
319
-125
-28% -$5.18K ﹤0.01% 13216
2023
Q3 		$26.9K Buy
444
+188
+73% +$17.6K ﹤0.01% 12376
2023
Q2 		$26K Sell
256
-88
-26% -$12.1K ﹤0.01% 12501
2023
Q1 		$60.9K Sell
344
-234
-40% -$78.4K ﹤0.01% 11911
2022
Q4 		$223K Buy
578
+156
+37% +$59.2K ﹤0.01% 9919
2022
Q3 		$142K Sell
422
-92
-18% -$33.3K ﹤0.01% 10773
2022
Q2 		$169K Buy
514
+89
+21% +$31.2K ﹤0.01% 10864
2022
Q1 		$186K Sell
425
-483
-53% -$198K ﹤0.01% 11623
2021
Q4 		$398K Sell
908
-1,250
-58% -$628K ﹤0.01% 10236
2021
Q3 		$1.2M Buy
2,158
+650
+43% +$326K ﹤0.01% 7677
2021
Q2 		$775K Sell
1,508
-3,286
-69% -$2.08M ﹤0.01% 9027
2021
Q1 		$3.75M Buy
4,794
+3,716
+345% +$2.54M ﹤0.01% 4918
2020
Q4 		$587K Buy
1,078
+500
+87% +$262K ﹤0.01% 7856
2020
Q3 		$265K Sell
578
-364
-39% -$211K ﹤0.01% 8357
2020
Q2 		$580K Sell
942
-386
-29% -$213K ﹤0.01% 6807
2020
Q1 		$631K Buy
1,328
+228
+21% +$124K ﹤0.01% 6107
2019
Q4 		$638K Sell
1,100
-547
-33% -$384K ﹤0.01% 6415
2019
Q3 		$1.08M Sell
1,647
-72
-4% -$59.9K ﹤0.01% 5461
2019
Q2 		$1.33M Buy
1,719
+1,080
+169% +$759K ﹤0.01% 5231
2019
Q1 		$451K Sell
639
-1,480
-70% -$886K ﹤0.01% 6962
2018
Q4 		$992K Buy
2,119
+763
+56% +$492K ﹤0.01% 5316
2018
Q3 		$1.17M Buy
1,356
+773
+133% +$558K ﹤0.01% 5274
2018
Q2 		$402K Buy
+583
New +$296K ﹤0.01% 6732
2017
Q4 		– Sell
-364
Closed -$179K – 8525
2017
Q3 		$179K Sell
364
-725
-67% -$363K ﹤0.01% 6774
2017
Q2 		$603K Sell
1,089
-467
-30% -$296K ﹤0.01% 4861
2017
Q1 		$1.03M Buy
1,556
+1,098
+240% +$587K ﹤0.01% 3946
2016
Q4 		$153K Sell
458
-256
-36% -$82.2K ﹤0.01% 6497
2016
Q3 		$215K Buy
+714
New +$155K ﹤0.01% 6209
2016
Q1 		– Sell
-22
Closed -$13K – 8156
2015
Q4 		$13K Sell
22
-28
-56% -$15.4K ﹤0.01% 8182
2015
Q3 		$26K Buy
+50
New +$33.5K ﹤0.01% 8020

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Citadel Advisors's TVRD Position: Q3 2024 in Review

Citadel Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 1,266 shares — an estimated $11.8K sold.

Citadel Advisors first reported a position in TVRD in Q3 2015 and held it in 32 quarters. The position peaked at $7.76M in Q3 2019. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Citadel Advisors reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,266 Tvardi Therapeutics shares in Q3 2024, an estimated $11.8K.
  • Citadel Advisors first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 32 quarters.
  • Citadel Advisors's Tvardi Therapeutics position peaked at $7.76M in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.